Of these kinases, contribution of Chk2 to cis-Pt resistance is possible as defects in this kinase and p53 are reported to be mutually exclusive [18] and Chk2 dysfunction is known to exist in several cancers [7], including 23% of clinical ovarian cancer cases [19]. This evidence concerns the gene TP53 and ovarian carcinoma.